title: Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients.
abstract: OBJECTIVE
  Aberrant expression of cyclin B1, a cell cycle regulator, is related to prognosis in various human malignancies. Additionally, cytoplasmic expression of cyclin B1 in epithelial malignancies is associated with a specific T-cell response and presumably also a humoral immune response. We therefore investigated (i) whether a similar expression pattern could be detected in native human acute myelogenous leukemia (AML) cells and (ii) whether cyclin B1 specific antibodies could be detected in AML.
  
  
  METHODS
  AML cell expression of cyclin B1 was analyzed by flow cytometry and confocal microscopy. Humoral immune response in AML patient sera against cyclin B1 was analyzed by ELISA.
  
  
  RESULTS
  AML cell expression of cyclin B1 was detected for all 42 patients; but the percentage of cyclin B1 positive cells showed a wide variation between patients. Confocal microscopy demonstrated that 32/42 (76%) patient samples showed abnormal cytoplasmic expression. Furthermore, the cytoplasmic expression was maintained after 14 d of in vitro culture and differentiation of the AML cells towards a dendritic cell phenotype. Cyclin B1 specific serum antibodies could be detected for seven of 65 patients with untreated AML.
  
  
  CONCLUSIONS
  Our studies demonstrate that primary human AML cells show aberrant cytoplasmic expression of cyclin B1 for a majority of patients and a specific humoral immune response was also detected for a subset of patients with untreated leukemia.
authors.affiliation: Institute of Medicine, University of Bergen, Bergen, Norway. elisabeth.ersvar@med.uib.no
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Ersvaer
authors.forename: Jian-Ying
authors.initials: JY
authors.lastname: Zhang
authors.forename: Emmet
authors.initials: E
authors.lastname: McCormack
authors.forename: Astrid
authors.initials: A
authors.lastname: Olsnes
authors.forename: Nina
authors.initials: N
authors.lastname: Anensen
authors.forename: Eng M
authors.initials: EM
authors.lastname: Tan
authors.forename: Bjørn Tore
authors.initials: BT
authors.lastname: Gjertsen
authors.forename: Oystein
authors.initials: O
authors.lastname: Bruserud
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood*; D000917:Antibody Formation; D000951:Antigens, Neoplasm; D016022:Case-Control Studies; D002454:Cell Differentiation; D002467:Cell Nucleus / Q000737:chemistry; D019926:Cyclin B / Q000032:analysis / Q000276:immunology*; D056744:Cyclin B1; D003593:Cytoplasm / Q000737:chemistry*; D003713:Dendritic Cells; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000276:immunology* / Q000473:pathology*; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D009368:Neoplasm Transplantation; D014183:Transplantation, Heterologous
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C534699:CCNB1 protein, human; C534700:Ccnb1 protein, mouse; D019926:Cyclin B; D056744:Cyclin B1